期刊文献+

IL-37抑制脂多糖诱导的小鼠树突状细胞活化 被引量:9

Interleukin-37 inhibits the activation of mouse dendritic cells induced by lipopolysaccharides
下载PDF
导出
摘要 目的探讨白细胞介素37(IL-37)对细菌脂多糖(LPS)诱导的小鼠树突状细胞(DC)活化的调节作用。方法应用GM-CSF和IL-4诱导小鼠骨髓细胞向DC分化,抗CD11c磁珠分选DC。IL-37预处理DC后,进行LPS刺激。流式细胞术检测DC表面共刺激分子(CD80、CD86)表达水平,实时荧光定量PCR检测肿瘤坏死因子α(TNF-α)、IL-6和IL-1αmRNA表达水平,流式细胞微球芯片试剂盒(CBA试剂盒)检测细胞培养上清中IL-1α、IL-6、TNF-α等因子的浓度。结果 DC诱导成功,磁珠分选能够获得高纯度的DC(>90%)。IL-37降低LPS诱导的DC表面共刺激分子CD80、CD86的表达,并抑制DC合成IL-1α、IL-6、TNF-α。结论 IL-37可以通过降低共刺激分子和炎症因子的表达抑制LPS刺激的DC活化。 Objective To investigate the role of interleukin-37(IL-37) in regulating the activation of mouse dendritic cells(DCs) induced by lipopolysaccharides(LPS).Methods The mouse bone marrow cells was induced to differentiate into DCs with GM-CSF and IL-4.DCs were purified with anti-CD11 c immunomagnetic beads.After pretreated with IL-37,DCs were stimulated by LPS.Then the levels of co-stimulatory molecules CD80 and CD86 on DCs were detected by flow cytometry.The mRNA levels of inflammation cytokines tumor necrosis factor α(TNF-α),IL-6 and IL-1α were determined by real-time quantitative PCR.The protein levels of inflammatory cytokines IL-1α,IL-6,TNF-α were measured by cytometric beads array(CBA) kit.Results We induced successfully DCs and obtained a high purity of DCs( 〉90%) with anti-CD11 c immunomagnetic beads.After stimulated by LPS,the levels of co-stimulating molecules CD80,CD86 on IL-37-treated DCs were reduced,and the expressions of the cytokines TNF-α,IL-6 and IL-1α were also down-regulated at both mRNA and protein levels.Conclusion IL-37 plays a critical role in inhibiting LPS-induced DCs activation via suppressing production of co-stimulatory molecules CD80,CD86 and pro-inflammatory cytokines.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2015年第4期433-436,442,共5页 Chinese Journal of Cellular and Molecular Immunology
基金 国家重大科学研究计划(2013CB966904) 国家自然科学基金(81273217) 天津市应用基础及前沿技术研究计划(12JCYBJC32800) 高等学校博士学科点专项科研基金(20121106120037)
关键词 白细胞介素37 树突状细胞 炎症因子 脂多糖 interleukin-37 dendritic cells inflammatory cytokines lipopolysaccharides
  • 相关文献

参考文献6

二级参考文献105

  • 1尚鹏,朱平,樊春梅,王彦宏.RANK RANKL和骨保护素在类风湿关节炎患者外周血和滑液中表达的研究[J].中华风湿病学杂志,2005,9(7):417-420. 被引量:14
  • 2刘军权 韩慧敏 陈复兴.用乳酸脱氢酶试剂盒检测LAK细胞活性.临床检验杂志,1995,.
  • 3Romas E, Gillespie MT, Martin TJ. Involvement of receptor acti- vator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone, 2002, 30: 340- 346.
  • 4Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoelast differentiation and activation. Cell, 1998, 93: 165-176.
  • 5Anderson DM, Maraskovsky E, Billingsley WL, et al. A homo- logue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 1997, 390: 175-179.
  • 6Kong YY, Feige U, Sarosi I, et al Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteo- protegerin ligand. Nature, 1999, 402: 304-309.
  • 7Sakata M, Shiba H, Komatsuzawa H, et al. Expression of osteo- protegerin (osteoclastogenesis inhibitory factor) in cultures of hu- man dental mesenchymal cells and epithelial cells. J Bone Miner Res, 1999, 14: 1486-1492.
  • 8~idal NO, Brandstrom H, Jonsson KB, et al. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J Endocrinol, 1998, 159: 191-195.
  • 9Collin-Osdoby P, Rothe L, Anderson F, et al. Receptor activa- tor of NF-kappa B and osteoprotegerin expression by human mi- crovascular endothelial ceils, regulation by inflammatory cy- toklnes, and role in human osteoclastogenesis. J Biol Chem, 2001, 276: 20659-20672.
  • 10Mitani M, Miura Y, Saura R, et al. Estrogen specifically stimu- lates expression and production of osteoprotegerin from rheuma- toid synovial fibroblasts. Int J Mol Med, 2005, 15: 827-832.

共引文献41

同被引文献82

  • 1朱江,高欣,谢文利,晋玉章,孙文军.京尼平苷对类风湿性关节炎大鼠血清IL-1β和TNF-α的影响[J].中国中药杂志,2005,30(9):708-711. 被引量:22
  • 2付丽红,丛斌,甄艳凤,李淑瑾,马春玲,倪志宇,张国忠,左敏,姚玉霞.类风湿性关节炎患者外周血单个核细胞IL-10基因启动子甲基化状态研究[J].遗传,2007,29(11):1357-1361. 被引量:12
  • 3Palomo J, Dietrich D, Martin P, et al. The interleukin (IL)-I eytokinc family-Balance between agonists and antagonists in inflammatory diseases[J]. Cytokine, 2015, 76(1): 25-37.
  • 4Ianaao C, Arced W, Sims J, et al. IL-1 family nomeftlatare[ J/OL]. Nat Immunol, 2010, 11 ( 11 ) : 973. doi: 10. 1038/ni1110 -973.
  • 5Garlanda C, Dinarello C A, Mantovani A. The interleukin-1 family: back to the futureI J]. Immunity, 2013, 39(6) : 1003 -1018.
  • 6Dinarello C A. Overview of the interleukin-1 family of ligands and receptors[ J]. Semin Immunol, 2013, 25 (6) : 389 - 393.
  • 7Xu W D, Zhao Y, Liu Y. Insights into IL-37, the role in autoimmune diseases[J]. Autoimmun Rev, 2015, 14(12) : 1170 - 1175.
  • 8Quirk S, Agrawal D K. Immunobiology of IL-37: mechanism of action and clinical perspectives [ J ]. Expert Rev Clin Immunol, 2014, 10(12): 1703-1709.
  • 9Boraschi D, lmcohesi D, Hainzl S, et al. IL-37: a new anti-inflarmnatory eytokine of the IL-1 family[J]. Eur Cytokine Netw, 2011, 22(3) : 127 - 147.
  • 10Taylor S L, Renshaw B R, Garka K E, et al. Genomic organization of the interleukin-1 locus[J]. Genomics, 2002, 79(5) : 726 -733.

引证文献9

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部